September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…
NEW DELHI, Aug. 23, 2025 /PRNewswire/ -- Ram Rattan Group has launched The Green Step Farms Phase 2 and Aravalli…
A Deep-skilling Initiative to Advance Hexaware's Agentic AI Capabilities MUMBAI, India and LONDON and ISELIN, N.J., Aug. 19, 2025 /PRNewswire/ --…
THIRUVANANTHAPURAM, India, Aug. 18, 2025 /PRNewswire/ -- The first phase of the International Institute of People with Disabilities (IIPD) in…
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…
CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in…
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…